BRANFORD, Conn., Sept. 5 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, announced today that Dr. Frank M. Armstrong, President and Chief Executive Officer, will present an update on the Company at the Bear Stearns 20th Annual Healthcare Conference on Tuesday, September 11, 2007, at 11:00 a.m. Eastern time. The conference is being held at The Grand Hyatt New York in New York City on September 10-11, 2007.
Access to a live webcast of the presentation and the accompanying slides will be available from the Investor Relations section of CuraGen's website at http://www.curagen.com . A replay of the webcast will be available after the presentation and archived for 30 days thereafter.
About CuraGen
CuraGen Corporation is a dedicated clinical-stage biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics for the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com .
CuraGen Contact: Glenn Schulman, Pharm.D. Director of Investor Relations gschulman@curagen.com (888) 436-6642 CRGN-G
CuraGen CorporationCONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen, +1-888-436-6642, gschulman@curagen.com
Web site: http://www.curagen.com//
